To assess whether β2AR‐blockers could potentiate the anti‐tumor effect of either melphalan or bortezomib in vitro, LP‐1 cells were pretreated for 3 days at a low concentration of propranolol (10, 25, or 35 μm) and then bortezomib or melphalan was added to the culture for 48 h (Figure 6A). This evidence concerns the gene ADRB2 and neoplasm.